These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload. Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD. Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017 [Abstract] [Full Text] [Related]
5. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload. Chen CH, Shu KH, Yang Y. Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910 [Abstract] [Full Text] [Related]
6. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R. Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987 [Abstract] [Full Text] [Related]
8. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Cheong JW, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH, Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party. Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463 [Abstract] [Full Text] [Related]
13. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Gattermann N, Jarisch A, Schlag R, Blumenstengel K, Goebeler M, Groschek M, Losem C, Procaccianti M, Junkes A, Leismann O, Germing U. Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452 [Abstract] [Full Text] [Related]
14. [The role of iron metabolism in myelodysplastic syndromes]. Finelli C, Clissa C, Stanzani M. Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455 [Abstract] [Full Text] [Related]
15. Iron chelation therapy in myelodysplastic syndrome - Cui bono? Tefferi A, Stone RM. Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273 [No Abstract] [Full Text] [Related]
16. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study. Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O, Hehlmann R, Hastka J. Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781 [Abstract] [Full Text] [Related]
17. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies. Fragomeno C, Roccabruna E, D'Ascola DG. Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263 [Abstract] [Full Text] [Related]
19. Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P, Ciccone F, Spadea A, Breccia M, Maurillo L, Rago A, Spirito F, Cedrone M, De Muro M, Montanaro M, Andriani A, Bagnato A, Montefusco E, Alimena G. Eur J Haematol; 2016 Jun; 96(6):643-9. PubMed ID: 26277477 [Abstract] [Full Text] [Related]
20. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920 [Abstract] [Full Text] [Related] Page: [Next] [New Search]